Obigen Pharma Inc. (TPEX:7876)
Taiwan
· Delayed Price · Currency is TWD 35.65
-0.95 (-2.60%)
At close: Mar 9, 2026
Obigen Pharma Company Description
Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin.
Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial.
The company was founded in 2020 and is based in Zhubei, Taiwan.
Obigen Pharma Inc.
| Country | Taiwan |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 57 |
| CEO | Peifen Chou |
Contact Details
Address: No. 66, Shengyi 5th Road Zhubei, 302041 Taiwan | |
| Phone | 886 2 2786 1217 |
| Website | obigenpharma.com |
Stock Details
| Ticker Symbol | 7876 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peifen Chou | Chief Executive Officer |
| Sheila Chuang | Chief Financial Officer |